These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15846461)

  • 21. Evaluation of type I error rates when modeling ordered categorical data in NONMEM.
    Wählby U; Matolcsi K; Karlsson MO; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Feb; 31(1):61-74. PubMed ID: 15346852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.
    Kowalski KG; Hutmacher MM
    J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):253-75. PubMed ID: 11468940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.
    Bertrand J; Comets E; Mentre F
    J Biopharm Stat; 2008; 18(6):1084-102. PubMed ID: 18991109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sample-size calculations for multi-group comparison in population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    Pharm Stat; 2010; 9(4):255-68. PubMed ID: 19714737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validity of tests under covariate-adaptive biased coin randomization and generalized linear models.
    Shao J; Yu X
    Biometrics; 2013 Dec; 69(4):960-9. PubMed ID: 23848580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.
    White DB; Walawander CA; Liu DY; Grasela TH
    J Pharmacokinet Biopharm; 1992 Jun; 20(3):295-313. PubMed ID: 1522482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models.
    Haem E; Harling K; Ayatollahi SM; Zare N; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):55-66. PubMed ID: 28144841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A fast method for testing covariates in population PK/PD Models.
    Khandelwal A; Harling K; Jonsson EN; Hooker AC; Karlsson MO
    AAPS J; 2011 Sep; 13(3):464-72. PubMed ID: 21725709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.
    Bruno R; Iliadis MC; Lacarelle B; Cosson V; Mandema JW; Le Roux Y; Montay G; Durand A; Ballereau M; Alasia M
    J Pharmacokinet Biopharm; 1992 Dec; 20(6):653-69. PubMed ID: 1302767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Derivation of various NONMEM estimation methods.
    Wang Y
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):575-93. PubMed ID: 17620001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Automated covariate model building within NONMEM.
    Jonsson EN; Karlsson MO
    Pharm Res; 1998 Sep; 15(9):1463-8. PubMed ID: 9755901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple imputation of missing covariates in NONMEM and evaluation of the method's sensitivity to η-shrinkage.
    Johansson ÅM; Karlsson MO
    AAPS J; 2013 Oct; 15(4):1035-42. PubMed ID: 23868748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the likelihood ratio test and the variance-stabilising transformation-based tests for detecting association of rare variants.
    Xing G; Ku HC; Xing C
    Ann Hum Genet; 2013 Jul; 77(4):333-5. PubMed ID: 23488943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.
    Ribbing J; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):109-34. PubMed ID: 15379381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of pharmacokinetic studies for latent covariates.
    Lagishetty CV; Coulter CV; Duffull SB
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):87-97. PubMed ID: 22161222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.
    Wade JR; Beal SL; Sambol NC
    J Pharmacokinet Biopharm; 1994 Apr; 22(2):165-77. PubMed ID: 7815312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of ondansetron: a covariate analysis.
    de Alwis DP; Aarons L; Palmer JL
    Br J Clin Pharmacol; 1998 Aug; 46(2):117-25. PubMed ID: 9723819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.